

Morgan Stanley Provides Assistance to Unrepresented Entrepreneurs

Applications due March 31, 2023

Morgan Stanley

CURRENTLY ACCEPTING APPLICATIONS FOR 2023 COHORT



69

Number of companies that have participated in the Lab to date



\$157M

Total amount in additional funding to date that companies have received after participating in the Lab



\$673M

Combined valuation to date of companies that have participated in the Lab

“Our mission is to create a more inclusive investment landscape for underrepresented founders. We provide a unique opportunity for disruptive startups to access capital, accelerate their business and increase their visibility.”

Selma Bueno Global Head of Inclusive Ventures Group

Apply to Morgan Stanley's Inclusive Ventures Lab, an intensive 5-month program providing startups with much-needed access to capital - along with tools, resources, and the connections they need to grow and thrive.

[Apply now](#)

BioLabs Pegasus Park Celebrates One Year Anniversary!



BioLabs Pegasus Park brought the life science and healthcare innovation community

together to celebrate their one-year anniversary since the Grand Opening in March of 2022. Dr. Gabby Everett, (center) pointed out the amazing success and highlighted the outreach, events, and collaborations accomplished in one year's time!

BioLabs Pegasus Park tenants BioLum Sciences, Colossal Biosciences, EтираRX and Secretome Therapeutics shared how BioLabs has impacted their science and companies, and how they have found a collaborative ecosystem in North Texas.

Happy Anniversary BioLabs Pegasus Park!

Texas Turns its Attention to the Life Science Industry During 88th Legislative Session

Expand Access to Biomarker Testing in Texas



Join ACS CAN in calling on the Texas legislature to require appropriate coverage of biomarker testing for public and private insurance plans.

Progress in improving cancer outcomes increasingly involves the use of precision medicine, which uses information about a person's own genes or proteins to prevent, diagnose or treat diseases like cancer. Biomarker testing is an important step to accelerating precision medicine which includes targeted therapies that can lead to improved survivorship and better quality of life for cancer patients.

Not all communities are benefitting from the latest advancements in biomarker testing and precision medicine, in part because insurance coverage for biomarker testing is failing to keep pace with innovation. Thank you for joining us today in making a difference!

[Sign ACS CAN's petition](#)

Mental Health and Brain Research Institute of Texas



(from left to right) Rep. John Kuempel, Chair of Committee, Kathleen Otto, Behnaam Aazhang, PhD, Eric Boerwinkle, PhD, Rep. Senfronia Thompson, Rep. Tom Craddick, Nadine Craddick, Joshua Shulman, MD, PhD and Andy Keller, PhD

The Texas House Committee on Higher Education heard testimony for **HB15/HJR135** the Mental Health and Brain Research Institute of Texas (MBRIT) on Monday, March 20, 2023.

Funding the Mental Health and Brain Research Institute of Texas (MBRIT) is the right thing to do. It is an example of responsible government doing what is best for patients, the entire health system, and the State economy.

The cost of mental health and brain related diseases to our State is incalculable. MBRIT will improve the health of Texans while tackling the spiraling costs of mental health and neurological diseases.

If passed this legislation will once again mark Texas as a leader in advancing healthcare solutions and attract the best and the brightest to our State.

[Learn more about the HB15/HJR135](#)

FDA Takes Steps to Accelerate Gene Therapy Approval Using Biomarkers



The U.S. Food and Drug Administration is moving to optimize the development of gene therapies, including encouraging the use of biomarkers to accelerate approval of therapies for serious conditions.

The FDA will support biomarkers as substitutes for other biological indicators in gene-therapy clinical trials to help clinch "accelerated approval", says Peter Marks, MD, PhD.

[Read full press release](#)

ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Clinical Trial of RCT1100 for the Treatment of PCD



ReCode Therapeutics, a private, clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced that the first healthy volunteer participants have been dosed in a Phase 1 clinical trial of RCT1100, a first-in-class, mRNA-based genetic medicine for the treatment of people with primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene.

[Learn more about ReCode Therapeutics](#)

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation



Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announced that two abstracts related to the company's novel molecular glue SP-3164 have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19 at the Orange County Convention Center in Orlando, Florida and also virtually. Both abstracts highlight preclinical activity with SP-3164, one focused on non-Hodgkin's lymphoma (NHL) and the other on multiple myeloma (MM).

[Learn more about Salarius' abstracts](#)

Avantor Best in Bioprocessing Chromatography



Avantor, a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, has been accorded the Best Bioprocessing Company for Chromatography at the Asia-Pacific Bioprocessing Excellence Awards 2023 (ABEA).

The award recognizes Avantor's ongoing efforts to provide innovative chromatography solutions that enable biopharmaceutical manufacturers to optimize processes and enhance product quality.

[Read full press release](#)

Polsinelli Ranks as Top Dealmaker for M&A, Private Equity & Venture Capital



Polsinelli has been recognized in PitchBook's 2022 Global League Tables as being amongst the most active law firms for advising on mergers & acquisitions, private equity and venture capital deals.

Throughout 2022 alone, the firm's Mergers & Acquisitions Practice closed 333 deals with a total value of \$17 billion. The Polsinelli Private Equity Practice closed a total of 154 M&A transactions with more than \$8.4 billion in total transaction value across 13 industries.

[Read full press release](#)

UTSW New School of Public Health Recruits Leader to Launch Health Implementation Science Program

UTSouthwestern
Medical Center®



George Jackson, PhD, MHA

George Jackson, PhD, MHA, a Professor at Duke University Medical Center, has joined UT Southwestern's Peter O'Donnell Jr. School of Public Health as a Professor of Public Health and founding Director of the Program for Implementation Science and Practice.

"Dr. Jackson will be an integral part of the University's new School of Public Health," said Celette_Sugg Skinner, PhD, Interim Dean of the O'Donnell School of Public Health. The School, created to address health care needs in North Texas and beyond, is the 4th at UT Southwestern and its first added in 50 years.

[Read full press release](#)

Accepting Applications for 2023 Cohort Accelerator Programs Apply Now!



Apply to Health Wildcatters Accelerator Program to connect with a vast network of mentors and investors and accelerate your startup growth in a 3-month program with 8 to 12 other startups.

**Applications due
May 31, 2023**

[Apply now](#)



Apply to Techstars Accelerator Program to join one of their 3-month, mentorship-driven accelerators, receive up to \$120,000 in funding, get hands-on mentorship & access to the Techstars network for life.

**Applications due
June 7, 2023**

[Apply now](#)

Thank You BioNTX New & Renewing Members!



Building Group



Upcoming Events & Opportunities in North Texas



Homecoming Community Happy Hour
Health Wildcatters

Join Health Wildcatters for a Happy Hour to celebrate our 10 years!

March 28, 2023

[Learn more here](#)



2023 State of Entrepreneurship
The DEC Network

Join The DEC Network at the 2023 State of Entrepreneurship which has become a tradition for celebrating the people, places and passions that keep the North Texas startup ecosystem thriving.

March 29, 2023

[Learn more here](#)



18th Annual Chili Cook-off
BioHouston

Join BioHouston to network with the Houston life science community and gather for a good time with LOTS OF CHILI!

April 14, 2023

[Learn more here](#)



BioFest Invest 2023
BioMedSA

Join BioMedSA at their annual spring event that brings together potential investors from across the nation and Texas bioscience companies seeking investment funding.

April 19, 2023

[Learn more here](#)



Horman McFadden Scholarship Golf Tournament



Regeneron ISEF 2023

UNTHSC

Join UNTHSC at their gold tournament to help improve someone's life. Proceeds from the tournament help HSC team members and their dependents pursue higher education goals and change their lives for the better.

April 21, 2023

[Learn more here](#)

Society for Science

Join The Regeneron International Science and Engineering Fair (ISEF) to be a part of the world's largest pre-college STEM competition. To participate in this event, you can volunteer or become a judge.

May 13 - 19, 2023

[Learn more here](#)



2023 Research & Quality Symposium JPS Health Network

Join JPS Health Network for a free two-day event featuring research and quality abstracts.

Thursday evening's event will include a networking event showcasing abstract presentations and prize giveaways. Friday morning's virtual session will feature live poster and gallery presentations.

May 18 - 19, 2023

[Learn more here](#)

BioNTX works to build a strong bioscience and healthcare innovation community through collaborative peer to peer networking events and educational programming.

[Let us know about your event!](#)

[View the North Texas community calendar of events](#)

[Look at upcoming BioNTX events](#)



Join BioNTX

BioNTX delivers opportunities for Members to connect across the State. Join us and collaborate with others, receive industry insights and visibility. We serve as the voice and champion for the life science community in NTX.



March 24, 2023

<http://www.BioNTX.org> | 5000 Riverside Drive, Building 6, Suite 100E, Irving, TX 75039

[Unsubscribe kotto@biontx.org](mailto:kotto@biontx.org)

[Update Profile](#) | [Constant Contact Data
Notice](#)

Sent by kotto@biontx.org